|
Irido-corneal dysgenesis
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
FOXD3 variants increase the risk of anterior segment dysgenesis phenotypes in humans.
|
22815627 |
2012 |
|
Irido-corneal dysgenesis
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
FOXD3 variants increase the risk of anterior segment dysgenesis phenotypes in humans.
|
22815627 |
2012 |
|
Major Depressive Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Secondary cell-based analysis demonstrated that stresscopin and FoxD3 are increased in neurons of DLPFC gray matter of MDD subjects.
|
18045927 |
2007 |
|
Major Depressive Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
Secondary cell-based analysis demonstrated that stresscopin and FoxD3 are increased in neurons of DLPFC gray matter of MDD subjects.
|
18045927 |
2007 |
|
Aniridia
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Analysis of FOXD3 sequence variation in human ocular disease.
|
22815627 |
2012 |
|
Irido-corneo-trabecular dysgenesis (disorder)
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Analysis of FOXD3 sequence variation in human ocular disease.
|
22815627 |
2012 |
|
Unipolar Depression
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Gene expression profiling in postmortem prefrontal cortex of major depressive disorder.
|
18045927 |
2007 |
|
AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 1
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Vitiligo
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
In addition to a possible association of rs78645479 in FoxD3 with vitiligo, our data on the association of this FoxD3 variant with thyroid autoantibodies suggest a potential involvement of FoxD3 in thyroid immunoregulation.
|
26267147 |
2015 |
|
Hashimoto Disease
|
0.110 |
AlteredExpression
|
disease |
BEFREE |
We confirmed gene expression of FoxD3 in human thyroid tissue, which seemed elevated in thyroid tissue samples of some patients with GD and nonautoimmune goiter but not in patients with HT.
|
26267147 |
2015 |
|
Vitiligo
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Hashimoto Disease
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Meanwhile, low FOXD3 protein expression was significantly correlated with poor histopathological grading, lymph node metastasis, and poor prognosis of patients, indicating its potential as a tumor marker that may be of potential value as a therapeutic target for CRC.
|
31784734 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings demonstrate that FOXD3 acts as a tumor suppressor during anaplastic thyroid carcinogenesis and highlight its potential for clinical application.
|
28430585 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway.
|
27926503 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study is the first to identify the tumor suppressor function of FoxD3 in lung cancer.
|
25894280 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings suggest that FOXD3 plays a potential tumor suppressor role in NSCLC progression and represents a promising clinical prognostic marker and therapeutic target for this disease.
|
26341266 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, FOXD3 was sufficient to suppress tumor growth and pulmonary metastatic potential in mice.
|
26112097 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A greater number of patients with invasive, triple-negative breast cancer were also negative for FoxD3 expression than in other, non-triple-negative tumor types.
|
24551288 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results indicate FOXD3 exhibits tumor suppressive activity and may be useful for breast therapy.
|
24632201 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
FOXD3-mediated transcriptional control of tumor suppressors is deregulated by H pylori infection-induced hypermethylation; this could perturb the balance between cell death and survival.
|
23058321 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results indicate that FOXD3 exhibits tumor suppressive activity that affects the growth, aggressiveness and angiogenesis of NB through transcriptional regulation of NDRG1.
|
24269992 |
2013 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
However, it is unclear whether FOXD3 plays any role in TIC and tumor metastasis.
|
30703266 |
2019 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
A further mechanistic study revealed that forkhead box D3 (FOXD3) was a direct target of miR‑425‑5p, and gain‑ and loss‑of‑function of FOXD3 studies demonstrated that FOXD3 suppressed HCC cell proliferation, migration, and invasion.
|
31257522 |
2019 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
A total of 1799 differentially methylated regions were identified including SLC6A3, Rab40C, ZNF584, and FOXD3 whose significant methylation differences were confirmed in breast cancer patients through quantitative real-time polymerase chain reaction.
|
28349825 |
2017 |